AngioDynamics (ANGO) Upgraded by BidaskClub to “Hold”

AngioDynamics (NASDAQ:ANGO) was upgraded by investment analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Monday.

Several other research analysts have also weighed in on the company. Zacks Investment Research lowered AngioDynamics from a “buy” rating to a “hold” rating in a research report on Friday, January 26th. Craig Hallum lowered AngioDynamics from a “buy” rating to a “hold” rating in a research report on Friday, January 5th. TheStreet lowered AngioDynamics from a “b-” rating to a “c” rating in a research report on Tuesday, January 2nd. Finally, Canaccord Genuity reaffirmed a “hold” rating and set a $17.00 price target on shares of AngioDynamics in a research report on Sunday, October 8th. Six equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $18.60.

Shares of AngioDynamics (NASDAQ:ANGO) traded down $0.58 during trading on Monday, reaching $16.67. The company had a trading volume of 402,706 shares, compared to its average volume of 316,779. AngioDynamics has a 1-year low of $14.80 and a 1-year high of $18.85. The firm has a market cap of $633.86, a price-to-earnings ratio of -79.38, a PEG ratio of 1.60 and a beta of 0.98. The company has a debt-to-equity ratio of 0.17, a quick ratio of 1.65 and a current ratio of 2.56.

AngioDynamics (NASDAQ:ANGO) last announced its earnings results on Thursday, January 4th. The medical instruments supplier reported $0.16 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.16. AngioDynamics had a positive return on equity of 4.63% and a negative net margin of 2.27%. The business had revenue of $86.70 million for the quarter, compared to analyst estimates of $88.15 million. During the same quarter last year, the firm earned $0.19 EPS. AngioDynamics’s revenue for the quarter was down 2.6% compared to the same quarter last year. analysts anticipate that AngioDynamics will post 0.72 EPS for the current fiscal year.

Large investors have recently bought and sold shares of the business. Teachers Advisors LLC increased its position in shares of AngioDynamics by 9.0% during the 2nd quarter. Teachers Advisors LLC now owns 84,021 shares of the medical instruments supplier’s stock worth $1,362,000 after purchasing an additional 6,928 shares during the last quarter. QS Investors LLC boosted its stake in shares of AngioDynamics by 37.3% during the 2nd quarter. QS Investors LLC now owns 42,351 shares of the medical instruments supplier’s stock worth $687,000 after acquiring an additional 11,504 shares during the period. Schwab Charles Investment Management Inc. boosted its stake in shares of AngioDynamics by 44.9% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 339,972 shares of the medical instruments supplier’s stock worth $5,511,000 after acquiring an additional 105,414 shares during the period. Wells Fargo & Company MN boosted its stake in shares of AngioDynamics by 0.9% during the 3rd quarter. Wells Fargo & Company MN now owns 1,025,233 shares of the medical instruments supplier’s stock worth $17,521,000 after acquiring an additional 9,639 shares during the period. Finally, Bessemer Group Inc. boosted its stake in shares of AngioDynamics by 13.9% during the 3rd quarter. Bessemer Group Inc. now owns 63,200 shares of the medical instruments supplier’s stock worth $1,080,000 after acquiring an additional 7,700 shares during the period. 94.75% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: “AngioDynamics (ANGO) Upgraded by BidaskClub to “Hold”” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://www.com-unik.info/2018/02/05/angiodynamics-ango-upgraded-by-bidaskclub-to-hold.html.

AngioDynamics Company Profile

AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.

Analyst Recommendations for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit